North Carolina State University

Becton Dickinson and Company Limited

Jim E Riviere

Burton H Sage

Ronald E Baynes

Nancy A Monteiro-Riviere

Xin-Rui Xia

Tomas Martin-Jimenez

Arthur L Craigmill

Richard A Rogers

A method of determining a molecular descriptor of absorption for a candidate compound is disclosed. The method includes: providing a test solution comprising one or more candidate compounds; contacting the test solution with a simulated biological membrane to partition the one or more candidate compounds into the membrane detecting the presence or amount of the one or more candidate compound in the membrane at one or more permeation times; and determining a molecular descriptor of absorption using the presence or amount of the one or more candidate compound in the membrane at the one or more permeation times. In one aspect the invention provides a skin-imitating membrane, and one or more percutaneous absorption parameters are determined. In another aspect the membrane is disposed on a fiber. In another aspect the test solution is contacted with two or more simulated biological membranes to partition the one or more candidate compounds into the membranes.

Method and apparatus for determining a molecular descriptor of absorption for a candidate compound

A first aspect of the invention is a method of estimating a withdrawal interval for an adjusted dose of a compound from a prior withdrawal time for a corresponding prior dose of that compound, corresponding half-life data and a tolerance concentration, for a tissue of interest. The method comprises selecting an adjusted dose for the compound for which a withdrawal interval is to be determined, and extrapolating a withdrawal interval from (a) the prior dose, (b) the prior withdrawal time, (c) the half-life data, and (d) the tolerance concentration. The process is useful for determining a withdrawal interval for an extralabel (i.e., non-approved) use of a drug in the same or a different jurisdiction for which a previous use has been approved, and can be used to determine an appropriate withdrawl interval for a drug in food products exported from one jurisdiction to another. Data processing systems and computer program products for carrying out the foregoing are also disclosed.

Methods, systems and products for determining drug withdrawal intervals

The present invention relates to the simultaneous administration of topical agents and systemic active agents to treat diseases of the skin and surrounding tissues, wherein the topical drug is applied to a treatment area and affects the concentration or activity of the systemic drug in that area.

Methods of using topical agents with systemically administered active

The iontophoretic device of the present invention comprises (a) a source for providing an electrical signal, (b) an electrode mounting block having a plurality of separate openings formed therein in spaced-apart relation from one another, with each of the openings configured to receive an iontophoresis electrode, (c) a plurality of iontophoresis electrodes electrically connected to the source and capable of transmitting electrical signal, each of the iontophoresis electrodes having a skin contact surface and each of the iontophoresis electrodes being received in one of the openings formed in the electrode mounting block, (d) a signal distribution network electrically connected to both the source and each of the plurality of electrodes and configured for distributing a electrical signal to each of the plurality of electrodes, and (e) a receiver connected to the source for accepting electrical signal transmitted by the plurality of electrodes, with the receiver of sufficient capacity to simultaneously accept electrical signal transmitted by each of the plurality of electrodes.

Iontophoretic electrode

The invention discloses methods and compositions for enhanced skin concentration of iontophoretic delivered active agents. The compositions are pharmaceutically acceptable compositions for iontophoretic delivery which comprise a skin concentration enhancing amount of a vasoconstrictor and active agent. Methods comprise adding a skin concentration enhancing amount of a vasoconstrictor to an active agent and delivering by iontophoresis.

Method and composition for increased skin concentration of active agents

The invention discloses methods and compositions for enhanced iontophoretic delivery of active agents. The compositions are pharmaceutically acceptable compositions for iontophoretic delivery comprising a delivery enhancing amount of a vasodilator and active agent. Methods comprise adding a delivery enhancing amount of a vasodilator to an active agent and delivering by iontophoresis.

Growing community of inventors

Raleigh, NC, United States of America

Jim E Riviere